Ranbaxy Q4 net loss at Rs 492 cr, sales fall 29%

Pharma major Ranbaxy reported a fourth quarter consolidated net loss of Rs 492 crore, lower than the Rs 2,983 crore loss it reported a year ago.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney Tech Control
moneycontrol.com

Home » News » Earnings » Results

Feb 27, 2013, 08.36 AM | Source: Moneycontrol.com

Ranbaxy Q4 net loss at Rs 492 cr, sales fall 29%

Pharma major Ranbaxy reported a fourth quarter consolidated net loss of Rs 492 crore, lower than the Rs 2,983 crore loss it reported a year ago.

Like this story, share it with millions of investors on M3

Ranbaxy Q4 net loss at Rs 492 cr, sales fall 29%

Pharma major Ranbaxy reported a fourth quarter consolidated net loss of Rs 492 crore, lower than the Rs 2,983 crore loss it reported a year ago.

Post Your Comments

Share Cancel

Moneycontrol Bureau

Pharma major Ranbaxy reported a fourth quarter consolidated net loss of Rs 492 crore, lower than the Rs 2,983 crore loss it reported a year ago. It must be noted that the company is negotiating a settlement with US Department of Justice for resolution of potential civil and criminal cases and had made a provision of Rs 2,648 crore for the same in the year ago quarter.

It also had foreign exchange loss of Rs 838 crore a year ago. Last quarter, the company had foreign exchange loss of about Rs 180 crore and it also set aside Rs 186 crore as costs related to the recall of select batches of its cholesterol lowering drug Atorvastatin Calcium from the US market.

Also Read: Ranbaxy restarts Atorvastatin production in the US

Ranbaxy incurred a loss from operations of near Rs 28 crore in Oct-Dec, versus a year ago profit of Rs 630 crore, excluding other income, finance costs and exceptional items.

The Japan's Daiichi Sankyo owned company's consolidated net sales in the fourth quarter declined 29 percent to Rs 2,671 crore.

While Ranbaxy's domestic sales rose 9 percent to Rs 548 crore, sales outside India slumped 35 percent year-on-year to Rs 2,123 crore. Its sales in the year-ago quarter were boosted by its exclusive launch of Atorvastatin, a generic version of Pfizer's Lipitor in the US market.

Ranbaxy shares closed down 4 percent at Rs 416.70 on NSE on Tuesday.

Buy, Hold, Sell ? Hear it first on M3
Ranbaxy Q4 net loss at Rs 492 cr, sales fall 29%

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login